Findings from a phase III clinical trial for advanced lung cancer patients could help oncologists better predict which patients are likely to receive the most benefit from immunotherapy as a first-line treatment based on the unique molecular characteristics of their tumor, according to a new study.
from Top Health News – ScienceDaily http://ift.tt/2tQ6d4W
from Tumblr http://ift.tt/2tvqMEw
No comments:
Post a Comment